Free Trial

Gilead Sciences (GILD) Stock Forecast & Price Target

$71.35
-1.06 (-1.46%)
(As of 01:37 PM ET)

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 19 Wall Street analysts who have issued ratings for Gilead Sciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 12 have given a hold rating, and 7 have given a buy rating for GILD.

Consensus Price Target

$82.88
16.16% Upside
High Forecast$105.00
Average Forecast$82.88
Low Forecast$69.00

According to the 19 analysts' twelve-month price targets for Gilead Sciences, the average price target is $82.88. The highest price target for GILD is $105.00, while the lowest price target for GILD is $69.00. The average price target represents a forecasted upside of 16.16% from the current price of $71.35.

TypeCurrent Forecast
7/24/23 to 7/23/24
1 Month Ago
6/24/23 to 6/23/24
3 Months Ago
4/25/23 to 4/24/24
1 Year Ago
7/24/22 to 7/24/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
9 Buy rating(s)
Hold
12 Hold rating(s)
12 Hold rating(s)
10 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$82.88$83.47$84.57$90.45
Forecasted Upside16.16% Upside18.88% Upside15.03% Upside10.72% Upside
Get Gilead Sciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

GILD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Gilead Sciences Stock vs. The Competition

TypeGilead SciencesMedical CompaniesS&P 500
Consensus Rating Score
2.37
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside16.70% Upside2,980.94% Upside9.55% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/22/2024Cantor Fitzgerald
3 of 5 stars
 Lower TargetNeutral ➝ Neutral$75.00 ➝ $70.00-3.38%
7/8/2024Raymond James
4 of 5 stars
 UpgradeMarket Perform ➝ Outperform$93.00+39.45%
7/1/2024Royal Bank of Canada
4 of 5 stars
 Reiterated RatingSector Perform ➝ Sector Perform$74.00 ➝ $74.00+5.80%
6/20/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$80.00 ➝ $80.00+15.82%
5/1/2024Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$90.00 ➝ $85.00+30.37%
4/29/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$80.00 ➝ $76.00+13.98%
4/26/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$80.00 ➝ $78.00+19.28%
4/26/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$90.00 ➝ $85.00+29.99%
4/26/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
4/24/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeReduce ➝ Hold$69.00+2.99%
4/19/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$105.00+58.01%
4/17/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$81.00 ➝ $75.00+12.06%
3/4/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$84.00 ➝ $77.00+6.49%
2/22/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$101.00 ➝ $90.00+24.76%
2/22/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$91.00 ➝ $82.00+12.02%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$75.00-3.72%
10/11/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Graybosch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
9/8/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$88.00 ➝ $95.00+28.48%
7/24/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$105.00 ➝ $100.00+26.34%
7/18/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$100.00 ➝ $95.00+22.61%
2/10/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$90.00 ➝ $95.00+11.07%
2/3/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetMarket Perform$81.00 ➝ $91.00+8.23%
12/9/2022DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$90.00+0.59%
11/9/2022Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$70.00 ➝ $100.00+21.61%
11/8/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$80.00 ➝ $90.00+9.45%
10/28/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$80.00 ➝ $87.00+11.72%
10/28/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$78.00 ➝ $86.00+10.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:08 PM ET.

GILD Forecast - Frequently Asked Questions

What is Gilead Sciences' forecast for 2024?

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Gilead Sciences is $82.88, with a high forecast of $105.00 and a low forecast of $69.00.

Should I buy or sell Gilead Sciences stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 12 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GILD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.

Does Gilead Sciences's stock price have much upside?

According to analysts, Gilead Sciences's stock has a predicted upside of 18.42% based on their 12-month stock forecasts.

Has Gilead Sciences been upgraded by Wall Street analysts recently?

Over the previous 90 days, Gilead Sciences's stock had 2 upgrades by analysts.

What analysts cover Gilead Sciences?

Gilead Sciences has been rated by research analysts at Barclays, Cantor Fitzgerald, HSBC, Maxim Group, Morgan Stanley, Needham & Company LLC, Raymond James, Robert W. Baird, Royal Bank of Canada, and TD Cowen in the past 90 days.

Do Wall Street analysts like Gilead Sciences more than its competitors?

Analysts like Gilead Sciences less than other "medical" companies. The consensus rating for Gilead Sciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GILD compares to other companies.


This page (NASDAQ:GILD) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners